Advanced Cancer Clinical Trials

A listing of 48 Advanced Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Advanced Cancer

1 - 12 of 48

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 48 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)

Recruiting

Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.

Conditions:

Obsessive-Compulsive Disorder

Obsessive Compulsive Disorder

Obsessive Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder (OCD)

Obsessive-compulsive Disorders and Symptoms

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? Join this online study from the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Learn More

Featured Trial

Gout Clinical Research Study

Recruiting

Struggling to manage gout flares? Are you familiar with the side effects of urate lowering treatments? You may be able to help our clinical study develop safer and more effective medicines to reduce uric acid and ease inflammation.

Eligible participants will receive study-related medical care at no cost.

Conditions:

Gout

Gout Flare

Acute Gout

Chronic Gout

Gout Attack

Learn More

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

NCT05663710

Recruiting

To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/27/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Advanced Cancer, Clear Cell Renal Cell Carcinoma

Learn More ›

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

NCT06120075

Recruiting

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Sarah Cannon Research Institute, Denver, Colorado +9 locations

Conditions: Advanced Cancer

Learn More ›

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171

Recruiting

The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/22/2025

Locations: Mayo Arizona, Phoenix, Arizona +13 locations

Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)

Learn More ›

Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer

NCT02112188

Recruiting

The purpose of the study is to modify a type of counseling called "Individual Meaning Centered Psychotherapy" to meet the needs of Chinese cancer patients. Many cancer patients use counseling or other resources to help cope with the emotional burden of their illnesses. Counseling often helps them cope with cancer by giving them a place to express their feelings. "Meaning-Centered" counseling aims to teach cancer patients how to maintain or even increase a sense of meaning and purpose in their li... Read More

Gender:

ALL

Ages:

Between 21 years and 80 years

Trial Updated:

01/15/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +8 locations

Conditions: Advanced Cancer

Learn More ›

Psilocybin Therapy in Advanced Cancer

NCT05398484

Recruiting

The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.

Gender:

ALL

Ages:

Between 21 years and 100 years

Trial Updated:

01/14/2025

Locations: University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado +1 locations

Conditions: Advanced Cancer

Learn More ›

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467

Recruiting

OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with fulvestrant or trastuzumab. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with standard dose fulvestrant (Part B) or standard dose trastuzum... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/06/2025

Locations: California Cancer Associates for Research and Excellence, Encinitas, California +25 locations

California Cancer Associates for Research and Excellence, Encinitas, California

Regents of the University of Colorado, Aurora, Colorado

Sarah Cannon Research Institute at HealthONE, Denver, Colorado

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Insitute, Detroit, Michigan

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Stony Brook University, Stony Brook, New York

SCRI Oncology Partners - Nashville, Nashville, Tennessee

NEXT Oncology Virginia, Fairfax, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Institut Jules Bordet, Anderlecht, Not set

GZA Hopsitals Campus Sint-Augustinus, Wilrijk, Not set

Centre de Lutte Contre le Cancer CLCC - Centre Georges Francois Leclerc (CGFL), Dijon, Not set

Centre Oscar Lambret, Lille, Not set

Centre Antoine Lacassagne, Nice, Not set

Institut Gustave Roussy, Villejuif, Not set

Ospedale San Gerardo-ASST Monza, Monza, Not set

Istituto Clinico Humanitas, Rozzano, Not set

Gachon University Gil Medical Center, Incheon, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

NEXT Oncology Phase I Unit / IOB- Hospital Quironsalud Barcelona, Barcelona, Not set

Hospital Beata Maria Ana, Madrid, Not set

START - Madrid, Madrid, Not set

Conditions: Advanced Cancer, Breast Cancer

Learn More ›

Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors

NCT04900818

Recruiting

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/02/2025

Locations: Stern Center for Cancer Clinical Trials and Research, Orange, California +20 locations

Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma

Learn More ›

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

Recruiting

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/19/2024

Locations: The Angeles Clinic and Research Institute, Los Angeles, California +9 locations

Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer

Learn More ›

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

NCT05853575

Recruiting

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/19/2024

Locations: Providence Medical Foundation, Santa Rosa, California +97 locations

Providence Medical Foundation, Santa Rosa, California

Local Institution - 106, Chicago, Illinois

Local Institution - 103, Minneapolis, Minnesota

Local Institution - 105, Kansas City, Missouri

Veterans Affairs Medical Center (VAMC) - Durham, Durham, North Carolina

VA North Texas Healthcare System/Dallas VA Medical Center, Dallas, Texas

Local Institution - 179, Cachoeiro Do Itapemirim, Espírito Santo

Local Institution - 178, Belo Horizonte, Minas Gerais

Local Institution - 177, Porto Alegre, Rio Grande Do Sul

Local Institution - 182, Itajaí, Santa Catarina

Local Institution - 181, Salvador, Not set

Local Institution - 175, São Paulo, Not set

Local Institution - 527, Zagreb, Grad Zagreb

Local Institution - 525, Pula, Not set

Hopital Haut-Leveque - Maladies respiratoires, Pessac, Gironde

Local Institution - 553, Saint-Herblain Cedex, Loire-Atlantique

Centre Hospitalier Universitaire D' Angers Hôpital Larrey - PNEUMOLOGIE, Angers, Maine-et-Loire

Centre Hospitalier Universitaire de Poitiers, Poitiers, Poitou-Charentes

Local Institution - 559, Grenoble, Rhône-Alpes

Local Institution - 560, Villefranche Sur Saone, Rhône

Centre Hôspitalier de Bretagne Sud - Hôpital du Scorff, Lorient, Not set

APHM Hopital Nord, Marseille, Not set

CHU de Nantes - Hôpital Nord Laënnec (HGRL), Nantes cedex 1, Not set

Local Institution - 558, Quimper, Not set

Hôpital Bégin - Service d'Oncologie, Saint-Mandé, Not set

Local Institution - 577, Patras, Achaïa

Local Institution - 575, Athens, Attiki

Local Institution - 582, Athens, Attiki

Local Institution - 579, Haidari - Athens, Attiki

Local Institution - 576, Thessaloniki, Kentriki Makedonia

Local Institution - 580, Panorama, Not set

Local Institution - 581, Thessaloniki, Not set

Local Institution - 628, Tel Aviv-Yafo, Tel-Aviv

Local Institution - 625, Jerusalem, Yerushalayim

Local Institution - 629, Haifa, Not set

Local Institution - 627, Haifa, Not set

Local Institution - 626, Tel-Aviv, Not set

Local Institution - 778, Pesaro, Pesaro E Urbino

Local Institution - 780, Candiolo, Torino

Local Institution - 779, Milano, Not set

Local Institution - 777, Novara, Not set

Local Institution - 775, Perugia, Not set

Local Institution - 776, Roma, Not set

National Cancer Center, Gyeonggido [Kyonggi-do], Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Gangnam Severance Hospital, Yonsei University Health System, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Not set

Local Institution - 128, Tuxtla Gutiérrez, Chiapas

Local Institution - 129, Cdmx, Distrito Federal

Local Institution - 127, Col. Roma, Distrito Federal

Local Institution - 125, Toluca, Not set

Local Institution - 802, Breda, Noord-Brabant

Local Institution - 800, Amsterdam, Noord-Holland

Local Institution - 801, Nieuwegein, Utrecht

Local Institution - 650, Krakow, Malopolskie

Local Institution - 651, Gdynia, Pomorskie

Local Institution - 653, Lublin, Not set

Local Institution - 732, Cluj-Napoca, Cluj

Local Institution - 731, Ovidiu, Constanta

Local Institution - 729, Craiova, Dolj

Local Institution - 734, Craiova, Dolj

Local Institution - 730, Timisoara, Timis

Local Institution - 733, Iasi, Not set

Local Institution - 725, Sibiu, Not set

Local Institution - 728, Suceava, Not set

Local Institution - 753, Belgrade, Beograd

Local Institution - 754, Nis, Niaavski Okrug

Local Institution - 752, Kragujevac, Šumadijski Okrug

Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, A Coruña

Local Institution - 678, Malaga, Andalucía

Local Institution - 676, Oviedo, Asturias

Local Institution - 685, Palma de Mallorca, Baleares

Local Institution - 684, Valencia, Valenciana, Comunidad

Local Institution - 687, Barcelona, Not set

Local Institution - 681, Barcelona, Not set

Local Institution - 683, Barcelona, Not set

Local Institution - 675, Madrid, Not set

Local Institution - 679, Madrid, Not set

Hospital Universitario Virgen De La Macarena, Sevilla, Not set

Local Institution - 677, Valencia, Not set

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsuing City, Kaohsiung

China Medical University Hospital - Internal Medicine, Taichung City, Taichung Municipality

Chung Shan Medical University Hospital, Taichung City, Taichung

Local Institution - 355, Taichung City, Taichung

Local Institution - 377, Bangkok, Krung Thep Maha Nakhon [Bangkok]

Local Institution - 376, Chiang Mai, Not set

Local Institution - 375, Khon Kaen, Not set

Local Institution - 378, Songkhla, Not set

Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi, Ankara, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, Not set

Memorial Ankara Hastanesi Tibbi Onkoloji, Ankara, Not set

Ankara Liv Hospital Tibbi Onkoloji, Ankara, Not set

Ankara Bilkent Sehir Hastanesi Tibbi Onkoloji Klinigi, Ankara, Not set

Trakya Univ Hastanesi Ic Hastal, Edirne, Not set

Local Institution - 709, Istanbul, Not set

Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Not set

Istanbul Onkoloji Hastanesi Tibbi Onkoloji, Istanbul, Not set

Local Institution - 708, Izmir, Not set

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

Learn More ›

Care Transition Intervention for Hospitalized Patients with Advanced Cancer

NCT05142345

Recruiting

This study is examining whether a care transition intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consisting of a supportive care-focused video visit with an oncology nurse practitioner (NP) within three business days of hospital discharge, may improve post-discharge transitions of care for recently hospitalized patients with advanced cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/19/2024

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Conditions: Cancer, Follow-Up Care, Consultation, Remote, Advanced Cancer

Learn More ›

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

NCT05877430

Recruiting

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities,... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/18/2024

Locations: University of California, Irvine, Irvine, California +3 locations

Conditions: NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer

Learn More ›

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045

Recruiting

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/11/2024

Locations: SCRI HealthOne, Denver, Colorado +7 locations

Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor

Learn More ›

1 - 12 of 48